Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Stereotactic Radiotherapy · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Stereotactic Radiotherapy | RADIATION | Stereotactic Radiotherapy |
Inclusion Criteria: * T1-T3N0 non-small cell lung cancer (maximum dimensions of 5cm, T3 by chestwall involvement only) * Medically inoperable due to co-morbid conditions or patient preference for radiation * adequate pulmonary function to withstand radical treatment (ie. FEV1 greater than 40% of pr...
Top 20 of 84 competitors
Stereotactic Radiotherapy is an investigational treatment being studied for early stage Non-small Cell Lung Cancer. It delivers precisely targeted radiation to the tumor. The therapy is currently in Phase 1 clinical development, with a completed Phase I/II study evaluating its use in this patient population.
Stereotactic Radiotherapy is being developed by Avalon GloboCare Corp., traded on the stock exchange under the ticker ALBT. The company is conducting clinical research to evaluate this radiation therapy approach for the treatment of Non-small Cell Lung Cancer.
Stereotactic Radiotherapy is in Phase 1 clinical development. A Phase I/II study of fractionated stereotactic radiotherapy for early stage Non-small Cell Lung Cancer has been completed. The therapy remains investigational and is not yet approved for commercial use.
Stereotactic Radiotherapy has one completed clinical trial, identified as NCT00888823. This was a Phase I/II study of fractionated stereotactic radiotherapy for early stage Non-small Cell Lung Cancer, conducted in Canada with 13 enrolled participants aged 18 years and older.
Stereotactic Radiotherapy is closely related to fractionated stereotactic radiotherapy, which is the specific technique evaluated in the clinical trial NCT00888823. The study title refers to fractionated stereotactic radiotherapy, indicating the delivery of radiation in multiple sessions for treating early stage Non-small Cell Lung Cancer.